Full metadata record
DC FieldValueLanguage
dc.creatorMartínez-Soldevilla, M. (Mario)-
dc.creatorVillanueva, H. (Helena)-
dc.creatorMeraviglia-Crivelli, D. (Daniel)-
dc.creatorMenon, A.P. (Ashwathi Puravankara)-
dc.creatorRuiz, M. (Marta)-
dc.creatorCebollero, J. (Javier)-
dc.creatorVillalba, M. (María)-
dc.creatorMoreno, B. (Beatriz)-
dc.creatorLozano, T. (Teresa)-
dc.creatorLlopiz, D. (Diana)-
dc.creatorPejenaute-Martínez-de-Lizarrondo, Á. (Álvaro)-
dc.creatorSarobe, P. (Pablo)-
dc.creatorPastor, F. (Fernando)-
dc.date.accessioned2022-03-02T09:06:12Z-
dc.date.available2022-03-02T09:06:12Z-
dc.date.issued2019-
dc.identifier.citationMartínez-Soldevilla, M. (Mario); Villanueva, H. (Helena); Meraviglia-Crivelli, D. (Daniel); et al. "ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity". Molecular Therapy. 27 (11), 2019, 1878 - 1891es_ES
dc.identifier.issn1525-0016-
dc.identifier.otherPMID 31405808-
dc.identifier.urihttps://hdl.handle.net/10171/62974-
dc.description.abstractCytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade therapy is able to induce long-lasting antitumor responses in a fraction of cancer patients. Nonetheless, there is still room for improvement in the quest for new therapeutic combinations. ICOS costimulation has been underscored as a possible target to include with CTLA-4 blocking treatment. Herein, we describe an ICOS agonistic aptamer that potentiates T cell activation and induces stronger antitumor responses when locally injected at the tumor site in combination with anti-CTLA-4 antibody in different tumor models. Furthermore, ICOS agonistic aptamer was engineered as a bi-specific tumor-targeting aptamer to reach any disseminated tumor lesions after systemic injection. Treatment with the bi-specific aptamer in combination with CTLA-4 blockade showed strong antitumor immunity, even in a melanoma tumor model where CTLA-4 treatment alone did not display any significant therapeutic benefit. Thus, this work provides strong support for the development of combinatorial therapies involving anti-CTLA-4 blockade and ICOS agonist tumor-targeting agents.es_ES
dc.description.sponsorshipThis work was supported by a Worldwide Cancer Research grant under grant 15-1208, Melanoma Research Alliance (509510), and Fundación Ramón Areces (CIVP18A3916). Instituto de Salud Carlos III cofunded Fondos FEDER (PI17/00372). F.P. was supported by Ramón y Cajal (10699). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 721358.es_ES
dc.language.isoenges_ES
dc.publisherElsevier BVes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectTarget therapeuticses_ES
dc.subjectCancer immunotherapyes_ES
dc.subjectICOSes_ES
dc.subjectCTLA-4es_ES
dc.subjectAptameres_ES
dc.titleICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunityes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).es_ES
dc.identifier.doi10.1016/j.ymthe.2019.07.013-
dadun.citation.endingPage1891es_ES
dadun.citation.number11es_ES
dadun.citation.publicationNameMolecular Therapyes_ES
dadun.citation.startingPage1878es_ES
dadun.citation.volume27es_ES

Files in This Item:
Thumbnail
File
PIIS1525001619303260.pdf
Description
Size
2.2 MB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.